Page 8 - Exosome Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation. Global Mesenchymal Stem Cells Advances and Applications Market Report 2021 - ResearchAndMarkets.com February 12, 2021 GMT DUBLIN--(BUSINESS WIRE)--Feb 12, 2021-- As the most common stem cell type being used within regenerative medicine today, there is huge potential for growth within the MSC market. There are more than one-hundred thousand scientific publications published about MSCs, as well as over 1,100 MSC clinical trials underway worldwide. ADVERTISEMENT Current “hotspots” for MSC clinical t...

Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 10, 2021 News provided by Share this article Share this article SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its third quarter fiscal year 2021, ended December 31, 2020, at 4:15 p.m. EST on Wednesday, February 10, 2021. Management will host a conference call on Wednesday, February 10, 2021 at 4:30 p.m. EST to review financial results ...

3.3.2 Bioinformatics Plays a Role 3.4 Diagnostic Technology Development 3.4.2 Impact of NGS on pricing 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment 3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magnetoresistance based assay 4. Liquid Biopsy Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section Liquid Biopsy NGS Panels - Diverse Test Claims CMS Colon Cancer Screening Memo Bodes Well for Assays Natera Liquid Biopsy Test Coverage to Expand Freenome Closes Financing to...

Liquid Biopsy Markets, 2025 with Impact of COVID-19 Pandemic February 02, 2021 04:43 ET | Source: Research and Markets Research and Markets Dublin, IRELAND ResearchAndMarkets.com's offering. The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring. The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Poten...

Share this article Share this article SAN DIEGO, Dec. 16, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the first patient has been treated in the Company's first-in-human Early Feasibility Study (EFS) evaluating the HEMOPURIFIER® in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The study is enrolling patients at UPMC Hillman Cancer Center in Pittsburgh, PA. ( The EFS, which is the device equivale...